Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023 providing projected cash runway into Q4 2024 LEXINGTON, Mass., May 12, 2023 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company … Read more